Vmbook Online ordering

Biotime Inc

I assume you are referring to the company Bio-Techne Corporation, which trades on the NASDAQ stock exchange under the ticker symbol BTX. Bio-Techne is a public biotechnology company that specializes in the development, manufacturing, and marketing of high-quality research and clinical tools, including bioproduction tools, reagents, and assays. The company operates through three business segments: BioTechnology Division, Clinical Diagnostics Division, and Protein Platforms Division.

Here is some general information about Bio-Techne:

H:

Bio-Techne's stock price has performed well over the past year, with its shares up around 50% over the past 12 months. The company has a market capitalization of approximately $13.3 billion and trades at a price-to-earnings ratio (P/E) of around 45.

Earnings:

Bio-Techne reported strong financial results for the third quarter of 2022, with revenue of $275 million, representing an increase of 25% year-over-year. The company's net income for the quarter was $58 million, or $1.28 per share, up from $43 million, or $0.91 per share, in the same period last year. For the first nine months of 2022, Bio-Techne's revenue increased by 24% year-over-year to $778 million, while its net income increased by 45% to $152 million, or $3.15 per share.

Growth:

Bio-Techne has been experiencing robust growth in recent years, driven by its strong product portfolio, strategic acquisitions, and expanding end markets. The company has a diverse product portfolio that serves a broad range of customers in the research, clinical, and biopharmaceutical industries. Bio-Techne has also been expanding its geographic reach through strategic partnerships and acquisitions, including its acquisition of the bioproduction business of Merck KGaA in 2020.

In summary, Bio-Techne is a strong and growing biotechnology company with a solid financial performance, diverse product portfolio, and expanding geographic reach. The company's strong earnings growth and share price performance reflect its success in capitalizing on the growing demand for its high-quality research and clinical tools.